These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 22421321)

  • 1. Modification of the C16Y peptide on nanoparticles is an effective approach to target endothelial and cancer cells via the integrin receptor.
    Hamano N; Negishi Y; Fujisawa A; Manandhar M; Sato H; Katagiri F; Nomizu M; Aramaki Y
    Int J Pharm; 2012 May; 428(1-2):114-7. PubMed ID: 22421321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a Screening System for Targeting Carriers Using Peptide-Modified Liposomes and Tissue Sections.
    Negishi Y; Hamano N; Sato H; Katagiri F; Takatori K; Endo-Takahashi Y; Kikkawa Y; Nomizu M
    Biol Pharm Bull; 2018; 41(7):1107-1111. PubMed ID: 29962407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ligand-based targeted delivery of a peptide modified nanocarrier to endothelial cells in adipose tissue.
    Hossen MN; Kajimoto K; Akita H; Hyodo M; Ishitsuka T; Harashima H
    J Control Release; 2010 Oct; 147(2):261-8. PubMed ID: 20647023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PR_b-targeted PEGylated liposomes for prostate cancer therapy.
    Demirgöz D; Garg A; Kokkoli E
    Langmuir; 2008 Dec; 24(23):13518-24. PubMed ID: 18954096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PEGylated liposomal doxorubicin targeted to α5β1-expressing MDA-MB-231 breast cancer cells.
    Shroff K; Kokkoli E
    Langmuir; 2012 Mar; 28(10):4729-36. PubMed ID: 22268611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PHSCNK-Modified and doxorubicin-loaded liposomes as a dual targeting system to integrin-overexpressing tumor neovasculature and tumor cells.
    Dai W; Yang T; Wang X; Wang J; Zhang X; Zhang Q
    J Drug Target; 2010 May; 18(4):254-63. PubMed ID: 19824864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrin Targeting and Toxicological Assessment of Peptide-Conjugated Liposome Delivery Systems to Activated Endothelial Cells.
    Kermanizadeh A; Villadsen K; Østrem RG; Jensen KJ; Møller P; Loft S
    Basic Clin Pharmacol Toxicol; 2017 Apr; 120(4):380-389. PubMed ID: 27767251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experimental anticancer therapy with vascular-disruptive peptide and liposome-entrapped chemotherapeutic agent.
    Sochanik A; Mitrus I; Smolarczyk R; Cichoń T; Snietura M; Czaja M; Szala S
    Arch Immunol Ther Exp (Warsz); 2010 Jun; 58(3):235-45. PubMed ID: 20383751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A pH-responsive cell-penetrating peptide-modified liposomes with active recognizing of integrin αvβ3 for the treatment of melanoma.
    Shi K; Li J; Cao Z; Yang P; Qiu Y; Yang B; Wang Y; Long Y; Liu Y; Zhang Q; Qian J; Zhang Z; Gao H; He Q
    J Control Release; 2015 Nov; 217():138-50. PubMed ID: 26368312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a novel cyclic RGD peptide for multiple targeting approaches of liposomes to tumor region.
    Amin M; Mansourian M; Koning GA; Badiee A; Jaafari MR; Ten Hagen TLM
    J Control Release; 2015 Dec; 220(Pt A):308-315. PubMed ID: 26526970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclic RGDyK conjugation facilitates intracellular drug delivery of polymeric micelles to integrin-overexpressing tumor cells and neovasculature.
    Yin J; Li Z; Yang T; Wang J; Zhang X; Zhang Q
    J Drug Target; 2011 Jan; 19(1):25-36. PubMed ID: 20233083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tetraiodothyroacetic acid-tagged liposomes for enhanced delivery of anticancer drug to tumor tissue via integrin receptor.
    Lee S; Kim J; Shim G; Kim S; Han SE; Kim K; Kwon IC; Choi Y; Kim YB; Kim CW; Oh YK
    J Control Release; 2012 Dec; 164(2):213-20. PubMed ID: 22664473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting of polymeric nanoparticles to lung metastases by surface-attachment of YIGSR peptide from laminin.
    Sarfati G; Dvir T; Elkabets M; Apte RN; Cohen S
    Biomaterials; 2011 Jan; 32(1):152-61. PubMed ID: 20889205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The relationship between the cyclic-RGDfK ligand and αvβ3 integrin receptor.
    Mondal G; Barui S; Chaudhuri A
    Biomaterials; 2013 Aug; 34(26):6249-60. PubMed ID: 23702147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual-ligand modification of PEGylated liposomes shows better cell selectivity and efficient gene delivery.
    Kibria G; Hatakeyama H; Ohga N; Hida K; Harashima H
    J Control Release; 2011 Jul; 153(2):141-8. PubMed ID: 21447361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RGD-modified polymeric micelles as potential carriers for targeted delivery to integrin-overexpressing tumor vasculature and tumor cells.
    Wang Y; Wang X; Zhang Y; Yang S; Wang J; Zhang X; Zhang Q
    J Drug Target; 2009 Jul; 17(6):459-67. PubMed ID: 19527117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced gene transfection efficiency in CD13-positive vascular endothelial cells with targeted poly(lactic acid)-poly(ethylene glycol) nanoparticles through caveolae-mediated endocytosis.
    Liu C; Yu W; Chen Z; Zhang J; Zhang N
    J Control Release; 2011 Apr; 151(2):162-75. PubMed ID: 21376765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RGD and interleukin-13 peptide functionalized nanoparticles for enhanced glioblastoma cells and neovasculature dual targeting delivery and elevated tumor penetration.
    Gao H; Xiong Y; Zhang S; Yang Z; Cao S; Jiang X
    Mol Pharm; 2014 Mar; 11(3):1042-52. PubMed ID: 24521297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclic RGD peptide-conjugated polyplex micelles as a targetable gene delivery system directed to cells possessing alphavbeta3 and alphavbeta5 integrins.
    Oba M; Fukushima S; Kanayama N; Aoyagi K; Nishiyama N; Koyama H; Kataoka K
    Bioconjug Chem; 2007; 18(5):1415-23. PubMed ID: 17595054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of 64Cu- and 125I-radiolabeled bitistatin as potential agents for targeting alpha v beta 3 integrins in tumor angiogenesis.
    McQuade P; Knight LC; Welch MJ
    Bioconjug Chem; 2004; 15(5):988-96. PubMed ID: 15366951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.